ClinicalTrials.gg
RecruitingNCT04569149Updated Oct 27, 2026

Primordial Dwarfism Registry

An observational study in MOPDII, Meier-Gorlin Syndrome and Saul-Wilson Syndrome, sponsored by Nemours Children's Clinic. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Nemours Children's Clinic · Observational

How we know

From the registry’s dates

  • Started Mar 2008; still recruiting 18 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
200
Sex
All
01

Study summary

The goal of this registry is to collect information on individuals with forms of microcephalic primordial dwarfism as well as related conditions. The study team hopes to learn more about these conditions and improve the care of people with them by establishing this registry.

Read the detailed description

The registry will enable detailed natural history studies of various forms of microcephalic primordial dwarfism as well as related conditions. The study team hopes that identification of risk factors will allow for preventative treatments and thus a better quality of life for individuals with these diagnoses.

This study is limited to chart review, after signed informed consent obtained. There will be no additional visits or time in clinic because of participation in this registry. This study involves only the collection and storage of data extracted from the medical record. Records that may be requested and reviewed as a part of this study include but may not be limited to: specialist evaluations, surgical reports, results of blood and urine tests, genetic testing, x-rays, CT/MRI/MRA imaging. There are no special procedures, visits, or expectations of the individual as a result of participation in this registry. No one will be asked to have any specific testing for the sole purposes of this research.

02

Conditions studied

  • MOPDII
  • Meier-Gorlin Syndrome
  • Saul-Wilson Syndrome
  • Microcephalic Primordial Dwarfism
  • IMAGe Syndrome
  • RNU4atac-opathy (e.g MOPDI, Lowry-Wood Syndrome, and Roifman Syndrome)
  • LIG4 Syndrome

Keywords

  • microcephalic primordial dwarfism
03

In context

Lead sponsor

Nemours Children's Clinic is the lead sponsor of 130 studies on the registry; 26 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any individual at any age with microcephalic primordial dwarfism or a closely related condition

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with MOPDII, Meier-Gorlin syndrome, IMAGe syndrome, RNU4atac-opathies (MOPDI/III, Roifman syndrome, Lowry-Wood syndrome), LIG4 syndrome, and other classified as well as unclassified types of microcephalic primordial dwarfism and related conditions, as diagnosed by a medical provider, are eligible for this registry.

Exclusion criteria

Exclusion Criteria:

  • individuals without microcephalic primordial dwarfism or closely related conditions
05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Characterization of the natural history of various forms of primordial dwarfism

    Data will be collected at enrollment, and over time, to allow for analysis of associated concerns throughout the lifespan

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2008 (actual). Primary completion is estimated for Jan 2030, 261 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Sep 29, 2020
StartActual
Mar 11, 2008
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04569149
Collaborators
Potentials Foundation, Walking with Giants Foundation
Responsible party
Angela Duker (Genetic Counselor/Coordinator of Skeletal Dysplasia Program, Nemours Children's Clinic) — Principal investigator
First posted
Sep 29, 2020
Start date
Mar 11, 2008
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Oct 27, 2026

Study contacts

Angela Duker, MS, CGC
Contact
aduker@nemours.org
302-651-4181
Emily Longenecker, BS
Contact
emily.longenecker@nemours.org
302-298-7978
Angela Duker, MS
principal investigator · Nemours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion